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Abstract 
Giant cell granuloma is a relatively rare benign entity but can be locally aggressive. Histologically characterized by 
intense proliferation of multinucleated giant cells and fibroblasts. Affects bone supported tissues. Definitive diag-
nosis is given by biopsy. Clinically manifest as a mass or nodule of reddish color and fleshy, occasionally ulcerated 
surface. They can range from asymptomatic to destructive lesions that grow quickly. It is a lesion to be considered 
in the differential diagnosis of osteolytic lesions affecting the maxilla or jaw. Its management passed from conser-
vative treatment with intralesional infiltration of corticosteroids, calcitonin or interferon, to the surgical resection 
and reconstruction, for example with microvascular free flaps.
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Introduction
Giant cell granuloma (GCGs) was first described by Ja-
ffe in 1953 (1) as “giant cell reparative granuloma”, but 
currently does not refer to him as reparative, because of 
its locally destructive. It is classified as peripheral if it 
affects the extremities and central if it develops in the 
midline (being the least common type). It is a relatively 
rare entity. Accounted for 7% of the maxillary tumors 
(his preferred location it´s the incisor region, and more 
frequently in the jaw than the maxilla) (2). It is more 
common in children and young adults, with a slight pre-
dominance in females (2). As etiological factors (3) have 
been related several factors, especially local irritants 
(such as extractions or poorly fitting dentures) and hor-
monal (4) (in fact, when we diagnose a GCGs, we should 
discard the coexistence of primary hyperparathyroidism, 
because classic brown tumors features of this disease are 
virtually indistinguishable from the histology of GCGs). 
Another theory relates to its origin it is an intraosseous 
vascular lesions similar to angiomas of soft tissues (5). 
In any case usually affects bone supported tissues.
                                          
Case Report
Female patient 16 years old with no history of interest 
who presents a lesion of several months, in the gingi-
va of the second quadrant, whose size, according to the 
patient, has not increased in recent weeks (Fig. 1a). It is 
clinically asymptomatic. On physical examination, the 
lesion is reddish, soft and fleshy. It causes a significant 
and bulging prominence, both lobby and palatal and mo-
bility of the pieces 22 and 23. The analytical requested 
in its health center is completely normal. Orthopantomo-
graphy shows the bone defect that coincides with lesion, 
pieces 18, 28, 38 and 48 included and root fragments of 
pieces 16 and 36, and periapical lesions in relation to 
pieces 36 and 37. When patient is attended in consulta-
tion, a facial, axial and coronal computed tomography 
(CT)-scan and 3D reconstructions are requested (Fig. 
1b), which shows the defect displayed on the Ortho-
pantomography. In  Hematoxylin-eosin staining appears 
intense proliferation of fibroblasts and multinucleated 
giant cells, and it is reported as “giant cell granuloma.” 
Based on the age of the patient, in the absence of clinical 
and benign nature of the lesion, we opted for conserva-
tive treatment by six cycles of intralesional injection of 
triamcinolone, with the further implementation of regu-
lar radiological controls. However, due to the persisten-
ce and escalation of the lesion (Fig. 2), we completed 
treatment with resection of the granuloma  and recons-
truction of the defect with microvascular fibula free flap 
with skin paddle associated  by anastomosis of the pe-
roneal vessels to the facial vessels (Fig. 3a). In a second 
procedure, two months after reconstruction, the flap was 
defatted (Fig. 3b).
Fig. 1. a Initial clinical view of the lesion. b View of the defect crea-
ted by the lesion in 3D reconstruction CT-scan.
Fig. 2. Appearance of the lesion after conservative treatment with 
intralesional triamcinolone.
                                           
Discussion
GCGs clinically manifests as a mass or nodule of reddish 
color (although it can sometimes be bluish) and occa-
sionally ulcerated fleshy surface. Its range can be from 
asymptomatic, small and slow-growing to large and des-
tructive lesions that grow rapidly. Imaging testing are es-
sential, because show the true extent of GCGs and their 
behavior in the tissue in which it sits. Although, as a first 
approximation we can make use of the Ortopantomogra-
phy, it is often necessary to perform  CT, sometimes even 
three-dimensional reconstructions. Definitive diagnosis 
is determined by biopsy. Thus, histologically characte-
rized (4) by the intense proliferation of multinucleated 
giant cells and fibroblasts, a dense vascular stroma with 
hemosiderin deposits. The differential diagnosis is made 
with pyogenic granuloma, gingival fibroma, fibrosarco-
ma and distant metastases of tumors, because they can 
resemble clinically GCGs.
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As for handling, typically resorted to surgery, from sim-
ple curettage to resection of the lesion. After the surgical 
treatment has a high rate of recurrence (between 13-
49%) (6). Currently calls for a conservative therapeutic, 
that prevents or diminishes the aesthetic and functional 
sequelae caused by standard treatments. So basically 
include three lines of conservative treatment. The most 
used is the intralesional injection of corticosteroids, with 
different guidelines and protocols, of which the most 
widespread in the literature is the weekly injection of 
triamcinolone (7) associated with local anesthetic for 
a period six weeks. Other conservative options are the 
use of calcitonin (8) (usually in the form of nasal spray) 
or interferon-α (INF-α) (4,8), both in pattern of several 
months, depending on the success in reducing the granu-
loma. Occasionally, due to the high recurrence rate or 
incomplete disappearance of GCGs with conservative 
treatment is necessary to supplement the treatment with 
surgical removal of the same, and if possible, recons-
truction of the defect created, for example with buccal 
fat pad flap (9) or microvascular free flaps, such as the 
fibula. Whatever the method chosen, it is essential to 
clinical and radiological control of the patient, through 
revisions and imaging testing (mainly CT).
We can conclude that  GCGs is a relatively rare entity of 
benign histologic nature but can have a very aggressive 
local behavior. A definitive diagnosis is reached by biop-
sy of the lesion. It should be present in the differential 
diagnosis in all expansive osteolytic lesions affecting the 
jaw or maxilla, such as pyogenic granuloma, gingival 
fibroma, fibrosarcoma and distant metastases of tumors. 
Its treatment includes from removal of it to the simple 
intralesional injection of corticosteroids or the use of 
calcitonin or INF-α, always with clinical and radiolo-
gical control due to its high rate of recurrence. Given 
the failure of conservative treatment, management be 
should an aggressive resection and reconstruction, when 
it is possible. An adequate solution is microvascular fi-
bula free flap.
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Fig. 3. a Adaptation of microvascular fibula free flap skin paddle 
associated to the resultant defect after excision. b Appearance of the 
flap once thinned two months after the reconstructive surgery.
